Pierrick Lefranc Appointed Executive Vice President at Ipsen
Ipsen has announced the appointment of Pierrick Lefranc as Executive Vice President (EVP) of Technical Operations and member of the Executive Leadership Team (ELT), effective from April 1, 2026.
Pierrick Lefranc will succeed Aidan Murphy, current EVP of Technical Operations and ELT member, who will retire next March after a 30-year career with the pharmaceutical company.
Lefranc brings over 30 years of experience in the pharmaceutical industry, having led large-scale manufacturing operations and industrial projects, "consistently improving productivity, quality, and regulatory compliance".
Since July 2019, he has served as Senior Vice President at Ipsen, overseeing global manufacturing activities, engineering, and business excellence. He joined the company in 2013 and was appointed site director at Signes, France, in 2016.
Currently, Aidan Murphy occupies the position of Executive Vice President-Technical Operations at Ipsen SA and Executive Vice-President-Technical Operations at Ipsen Pharma SAS (a subsidiary of Ipsen SA). He is also on the board of Ipsen Manufacturing Ireland Ltd.
In the past Aidan Murphy held the position of Managing Director at Ipsen Pharma SAS.
Dr. Murphy received a doctorate from Trinity College Dublin.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (69.2%);
- neuroscience (20.3%);
- rare diseases (10.5%).
At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.
Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
![Aidan Murphy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
